Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Sanofi, MJFF Collaborate On Potential New Treatment For Parkinson's Disease

Sanofi (SNY: Quote,SNYNF.PK) said it has entered into a collaboration with the Michael J. Fox Foundation, or MJFF, to conduct a clinical trial to assess the safety and tolerability of AVE 8112, a Sanofi PDE4 inhibitor - phosphodiesterase type 4 inhibitor - in patients with Parkinson's disease.

As per the terms of the collaboration, MJFF will sponsor a phase I b clinical trial to assess the safety and tolerability of AVE8112 in patients with Parkinson's disease. All data and results generated by the clinical trial will be owned by MJFF and shared with Sanofi. The company noted that further development plans will be based upon the results of the study.

Todd Sherer, chief executive officer of MJFF, stated, "AVE8112 has shown promising pro-cognitive activity in preclinical models that could be of interest to the under-addressed cognitive aspects of Parkinson's disease, an area of unmet need where a new treatment could make a tangible difference in patients' lives. Groundbreaking collaborations with like-minded partners such as Sanofi are a hallmark of the Fox Foundation's approach and help us speed scientific advances with potential to improve the treatment of Parkinson's for patients today and in the future."

Patient enrollment in the study is expected to begin later 2012.

Register
To receive FREE breaking news email alerts for Sanofi and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Suggesting moderate growth in the short-term, the Conference Board released a report on Thursday showing that its index of leading U.S. economic indicators rose by more than economists had anticipated in the month of September. Stocks have moved sharply higher in early trading on Thursday after turning lower over the course of the previous session. The major averages have climbed firmly into positive territory, more than offsetting yesterday's steep losses. Eurozone's consumer confidence improved unexpectedly in October after weakening in the previous four months, preliminary data from the European Commission showed Thursday. The flash consumer confidence indicator rose to -11.1 from a seven-month low of -11.4 in September. Economists had forecast a...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.